MersV1, PascalFrancis, Corpus, bibRecord, 000006

Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice

Identifieur interne : 000006 ( PascalFrancis/Corpus ); précédent : 000005; suivant : 000007

Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice

Auteurs : EUN KIM ; Kaori Okada ; Tom Kenniston ; V. Stalin Raj ; Mohd M. Alhajri ; Elmoubasher A. B. A. Farag ; Farhoud Alhajri ; Albert D. M. E. Osterhaus ; Bart L. Haagmans ; Andrea Gambotto

Source :

Vaccine [ 0264-410X ] ; 2014.

RBID : Pascal:14-0250779

Descripteurs français

Pascal (Inist)
- Coronavirus, Souris, Immunogénicité, Moyen Orient, Vaccin, Codon.

English descriptors

KwdEn :
- Codon, Coronavirus, Immunogenicity, Middle east, Mouse, Vaccine.

Abstract

A new type of coronavirus has been identified as the causative agent underlying Middle East Respiratory Syndrome (MERS). The MERS coronavirus (MERS-CoV) has spread in the Middle East, but cases originating in the Middle East have also occurred in the European Union and the USA. Eight hundred and thirty-seven cases of MERS-CoV infection have been confirmed to date, including 291 deaths. MERS-CoV has infected dromedary camel populations in the Middle East at high rates, representing an immediate source of human infection. The MERS-CoV spike (S) protein, a characteristic structural component of the viral envelope, is considered as a key target of vaccines against coronavirus infection. In an initial attempt to develop a MERS-CoV vaccine to ultimately target dromedary camels, we constructed two recombinant adenoviral vectors encoding the full-length MERS-CoV S protein (Ad5.MERS-S) and the S1 extracellular domain of S protein (Ad5.MERS-S1). BALB/c mice were immunized with both candidate vaccines intramuscularly and boosted three weeks later intranasally. All the vaccinated animals had antibody responses against spike protein, which neutralized MERS-CoV in vitro. These results show that an adenoviral-based vaccine can induce MERS-CoV-specific immune responses in mice and hold promise for the development of a preventive vaccine that targets the animal reservoir, which might be an effective measure to eliminate transmission of MERS-CoV to humans.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0264-410X`
A02	`01`			`@0 VACCDE`
A03		`1`		`@0 Vaccine`
A05				`@2 32`
A06				`@2 45`
A08	`01`	`1`	`ENG`	`@1 Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice`
A11	`01`	`1`		`@1 EUN KIM`
A11	`02`	`1`		`@1 OKADA (Kaori)`
A11	`03`	`1`		`@1 KENNISTON (Tom)`
A11	`04`	`1`		`@1 STALIN RAJ (V.)`
A11	`05`	`1`		`@1 ALHAJRI (Mohd M.)`
A11	`06`	`1`		`@1 FARAG (Elmoubasher A. B. A)`
A11	`07`	`1`		`@1 ALHAJRI (Farhoud)`
A11	`08`	`1`		`@1 OSTERHAUS (Albert D. M. E.)`
A11	`09`	`1`		`@1 HAAGMANS (Bart L.)`
A11	`10`	`1`		`@1 GAMBOTTO (Andrea)`
A14	`01`			`@1 Department of Surgery, University of Pittsburgh School of Medicine @2 Pittsburgh, PA 15224 @3 USA @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 10 aut.`
A14	`02`			`@1 Department of Viroscience, Erasmus Medical Center Rotterdam @2 Rotterdam @3 NLD @Z 4 aut. @Z 8 aut. @Z 9 aut.`
A14	`03`			`@1 Supreme Council of Health @2 Doha @3 QAT @Z 5 aut. @Z 6 aut.`
A14	`04`			`@1 Animal Resources Department - Ministry of Environment @2 Doha @3 QAT @Z 7 aut.`
A20				`@1 5975-5982`
A21				`@1 2014`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20289 @5 354000508274440140`
A44				`@0 0000 @1 © 2014 INIST-CNRS. All rights reserved.`
A45				`@0 56 ref.`
A47	`01`	`1`		`@0 14-0250779`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Vaccine`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 A new type of coronavirus has been identified as the causative agent underlying Middle East Respiratory Syndrome (MERS). The MERS coronavirus (MERS-CoV) has spread in the Middle East, but cases originating in the Middle East have also occurred in the European Union and the USA. Eight hundred and thirty-seven cases of MERS-CoV infection have been confirmed to date, including 291 deaths. MERS-CoV has infected dromedary camel populations in the Middle East at high rates, representing an immediate source of human infection. The MERS-CoV spike (S) protein, a characteristic structural component of the viral envelope, is considered as a key target of vaccines against coronavirus infection. In an initial attempt to develop a MERS-CoV vaccine to ultimately target dromedary camels, we constructed two recombinant adenoviral vectors encoding the full-length MERS-CoV S protein (Ad5.MERS-S) and the S1 extracellular domain of S protein (Ad5.MERS-S1). BALB/c mice were immunized with both candidate vaccines intramuscularly and boosted three weeks later intranasally. All the vaccinated animals had antibody responses against spike protein, which neutralized MERS-CoV in vitro. These results show that an adenoviral-based vaccine can induce MERS-CoV-specific immune responses in mice and hold promise for the development of a preventive vaccine that targets the animal reservoir, which might be an effective measure to eliminate transmission of MERS-CoV to humans.
C02	`01`	`X`		`@0 002A05F04`
C02	`02`	`X`		`@0 002A05C10`
C03	`01`	`X`	`FRE`	`@0 Coronavirus @2 NW @5 01`
C03	`01`	`X`	`ENG`	`@0 Coronavirus @2 NW @5 01`
C03	`01`	`X`	`SPA`	`@0 Coronavirus @2 NW @5 01`
C03	`02`	`X`	`FRE`	`@0 Souris @5 02`
C03	`02`	`X`	`ENG`	`@0 Mouse @5 02`
C03	`02`	`X`	`SPA`	`@0 Ratón @5 02`
C03	`03`	`X`	`FRE`	`@0 Immunogénicité @5 05`
C03	`03`	`X`	`ENG`	`@0 Immunogenicity @5 05`
C03	`03`	`X`	`SPA`	`@0 Inmunogenicidad @5 05`
C03	`04`	`X`	`FRE`	`@0 Moyen Orient @2 NG @5 06`
C03	`04`	`X`	`ENG`	`@0 Middle east @2 NG @5 06`
C03	`04`	`X`	`SPA`	`@0 Oriente Medio @2 NG @5 06`
C03	`05`	`X`	`FRE`	`@0 Vaccin @5 07`
C03	`05`	`X`	`ENG`	`@0 Vaccine @5 07`
C03	`05`	`X`	`SPA`	`@0 Vacuna @5 07`
C03	`06`	`X`	`FRE`	`@0 Codon @5 08`
C03	`06`	`X`	`ENG`	`@0 Codon @5 08`
C03	`06`	`X`	`SPA`	`@0 Codón @5 08`
C07	`01`	`X`	`FRE`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`ENG`	`@0 Coronaviridae @2 NW`
C07	`01`	`X`	`SPA`	`@0 Coronaviridae @2 NW`
C07	`02`	`X`	`FRE`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`ENG`	`@0 Nidovirales @2 NW`
C07	`02`	`X`	`SPA`	`@0 Nidovirales @2 NW`
C07	`03`	`X`	`FRE`	`@0 Virus @2 NW`
C07	`03`	`X`	`ENG`	`@0 Virus @2 NW`
C07	`03`	`X`	`SPA`	`@0 Virus @2 NW`
C07	`04`	`X`	`FRE`	`@0 Rodentia @2 NS`
C07	`04`	`X`	`ENG`	`@0 Rodentia @2 NS`
C07	`04`	`X`	`SPA`	`@0 Rodentia @2 NS`
C07	`05`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`05`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`05`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`06`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`06`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`06`	`X`	`SPA`	`@0 Vertebrata @2 NS`
C07	`07`	`X`	`FRE`	`@0 Asie @2 NG`
C07	`07`	`X`	`ENG`	`@0 Asia @2 NG`
C07	`07`	`X`	`SPA`	`@0 Asia @2 NG`
N21				`@1 307`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Format Inist (serveur)

NO :	PASCAL 14-0250779 INIST
ET :	Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice
AU :	EUN KIM; OKADA (Kaori); KENNISTON (Tom); STALIN RAJ (V.); ALHAJRI (Mohd M.); FARAG (Elmoubasher A. B. A); ALHAJRI (Farhoud); OSTERHAUS (Albert D. M. E.); HAAGMANS (Bart L.); GAMBOTTO (Andrea)
AF :	Department of Surgery, University of Pittsburgh School of Medicine/Pittsburgh, PA 15224/Etats-Unis (1 aut., 2 aut., 3 aut., 10 aut.); Department of Viroscience, Erasmus Medical Center Rotterdam/Rotterdam/Pays-Bas (4 aut., 8 aut., 9 aut.); Supreme Council of Health/Doha/Qatar (5 aut., 6 aut.); Animal Resources Department - Ministry of Environment/Doha/Qatar (7 aut.)
DT :	Publication en série; Niveau analytique
SO :	Vaccine; ISSN 0264-410X; Coden VACCDE; Royaume-Uni; Da. 2014; Vol. 32; No. 45; Pp. 5975-5982; Bibl. 56 ref.
LA :	Anglais
EA :	A new type of coronavirus has been identified as the causative agent underlying Middle East Respiratory Syndrome (MERS). The MERS coronavirus (MERS-CoV) has spread in the Middle East, but cases originating in the Middle East have also occurred in the European Union and the USA. Eight hundred and thirty-seven cases of MERS-CoV infection have been confirmed to date, including 291 deaths. MERS-CoV has infected dromedary camel populations in the Middle East at high rates, representing an immediate source of human infection. The MERS-CoV spike (S) protein, a characteristic structural component of the viral envelope, is considered as a key target of vaccines against coronavirus infection. In an initial attempt to develop a MERS-CoV vaccine to ultimately target dromedary camels, we constructed two recombinant adenoviral vectors encoding the full-length MERS-CoV S protein (Ad5.MERS-S) and the S1 extracellular domain of S protein (Ad5.MERS-S1). BALB/c mice were immunized with both candidate vaccines intramuscularly and boosted three weeks later intranasally. All the vaccinated animals had antibody responses against spike protein, which neutralized MERS-CoV in vitro. These results show that an adenoviral-based vaccine can induce MERS-CoV-specific immune responses in mice and hold promise for the development of a preventive vaccine that targets the animal reservoir, which might be an effective measure to eliminate transmission of MERS-CoV to humans.
CC :	002A05F04; 002A05C10
FD :	Coronavirus; Souris; Immunogénicité; Moyen Orient; Vaccin; Codon
FG :	Coronaviridae; Nidovirales; Virus; Rodentia; Mammalia; Vertebrata; Asie
ED :	Coronavirus; Mouse; Immunogenicity; Middle east; Vaccine; Codon
EG :	Coronaviridae; Nidovirales; Virus; Rodentia; Mammalia; Vertebrata; Asia
SD :	Coronavirus; Ratón; Inmunogenicidad; Oriente Medio; Vacuna; Codón
LO :	INIST-20289.354000508274440140
ID :	14-0250779

Links to Exploration step

Pascal:14-0250779

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice</title>
<author><name sortKey="Eun Kim" sort="Eun Kim" uniqKey="Eun Kim" last="Eun Kim">EUN KIM</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Surgery, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA 15224</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Okada, Kaori" sort="Okada, Kaori" uniqKey="Okada K" first="Kaori" last="Okada">Kaori Okada</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Surgery, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA 15224</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kenniston, Tom" sort="Kenniston, Tom" uniqKey="Kenniston T" first="Tom" last="Kenniston">Tom Kenniston</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Surgery, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA 15224</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stalin Raj, V" sort="Stalin Raj, V" uniqKey="Stalin Raj V" first="V." last="Stalin Raj">V. Stalin Raj</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Viroscience, Erasmus Medical Center Rotterdam</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alhajri, Mohd M" sort="Alhajri, Mohd M" uniqKey="Alhajri M" first="Mohd M." last="Alhajri">Mohd M. Alhajri</name>
<affiliation><inist:fA14 i1="03"><s1>Supreme Council of Health</s1>
<s2>Doha</s2>
<s3>QAT</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Farag, Elmoubasher A B A" sort="Farag, Elmoubasher A B A" uniqKey="Farag E" first="Elmoubasher A. B. A" last="Farag">Elmoubasher A. B. A. Farag</name>
<affiliation><inist:fA14 i1="03"><s1>Supreme Council of Health</s1>
<s2>Doha</s2>
<s3>QAT</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alhajri, Farhoud" sort="Alhajri, Farhoud" uniqKey="Alhajri F" first="Farhoud" last="Alhajri">Farhoud Alhajri</name>
<affiliation><inist:fA14 i1="04"><s1>Animal Resources Department - Ministry of Environment</s1>
<s2>Doha</s2>
<s3>QAT</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Viroscience, Erasmus Medical Center Rotterdam</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L." last="Haagmans">Bart L. Haagmans</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Viroscience, Erasmus Medical Center Rotterdam</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gambotto, Andrea" sort="Gambotto, Andrea" uniqKey="Gambotto A" first="Andrea" last="Gambotto">Andrea Gambotto</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Surgery, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA 15224</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">14-0250779</idno>
<date when="2014">2014</date>
<idno type="stanalyst">PASCAL 14-0250779 INIST</idno>
<idno type="RBID">Pascal:14-0250779</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000006</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice</title>
<author><name sortKey="Eun Kim" sort="Eun Kim" uniqKey="Eun Kim" last="Eun Kim">EUN KIM</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Surgery, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA 15224</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Okada, Kaori" sort="Okada, Kaori" uniqKey="Okada K" first="Kaori" last="Okada">Kaori Okada</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Surgery, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA 15224</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kenniston, Tom" sort="Kenniston, Tom" uniqKey="Kenniston T" first="Tom" last="Kenniston">Tom Kenniston</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Surgery, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA 15224</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Stalin Raj, V" sort="Stalin Raj, V" uniqKey="Stalin Raj V" first="V." last="Stalin Raj">V. Stalin Raj</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Viroscience, Erasmus Medical Center Rotterdam</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alhajri, Mohd M" sort="Alhajri, Mohd M" uniqKey="Alhajri M" first="Mohd M." last="Alhajri">Mohd M. Alhajri</name>
<affiliation><inist:fA14 i1="03"><s1>Supreme Council of Health</s1>
<s2>Doha</s2>
<s3>QAT</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Farag, Elmoubasher A B A" sort="Farag, Elmoubasher A B A" uniqKey="Farag E" first="Elmoubasher A. B. A" last="Farag">Elmoubasher A. B. A. Farag</name>
<affiliation><inist:fA14 i1="03"><s1>Supreme Council of Health</s1>
<s2>Doha</s2>
<s3>QAT</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Alhajri, Farhoud" sort="Alhajri, Farhoud" uniqKey="Alhajri F" first="Farhoud" last="Alhajri">Farhoud Alhajri</name>
<affiliation><inist:fA14 i1="04"><s1>Animal Resources Department - Ministry of Environment</s1>
<s2>Doha</s2>
<s3>QAT</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E." last="Osterhaus">Albert D. M. E. Osterhaus</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Viroscience, Erasmus Medical Center Rotterdam</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Haagmans, Bart L" sort="Haagmans, Bart L" uniqKey="Haagmans B" first="Bart L." last="Haagmans">Bart L. Haagmans</name>
<affiliation><inist:fA14 i1="02"><s1>Department of Viroscience, Erasmus Medical Center Rotterdam</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gambotto, Andrea" sort="Gambotto, Andrea" uniqKey="Gambotto A" first="Andrea" last="Gambotto">Andrea Gambotto</name>
<affiliation><inist:fA14 i1="01"><s1>Department of Surgery, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA 15224</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
<imprint><date when="2014">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Vaccine</title>
<title level="j" type="abbreviated">Vaccine</title>
<idno type="ISSN">0264-410X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Codon</term>
<term>Coronavirus</term>
<term>Immunogenicity</term>
<term>Middle east</term>
<term>Mouse</term>
<term>Vaccine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Coronavirus</term>
<term>Souris</term>
<term>Immunogénicité</term>
<term>Moyen Orient</term>
<term>Vaccin</term>
<term>Codon</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A new type of coronavirus has been identified as the causative agent underlying Middle East Respiratory Syndrome (MERS). The MERS coronavirus (MERS-CoV) has spread in the Middle East, but cases originating in the Middle East have also occurred in the European Union and the USA. Eight hundred and thirty-seven cases of MERS-CoV infection have been confirmed to date, including 291 deaths. MERS-CoV has infected dromedary camel populations in the Middle East at high rates, representing an immediate source of human infection. The MERS-CoV spike (S) protein, a characteristic structural component of the viral envelope, is considered as a key target of vaccines against coronavirus infection. In an initial attempt to develop a MERS-CoV vaccine to ultimately target dromedary camels, we constructed two recombinant adenoviral vectors encoding the full-length MERS-CoV S protein (Ad5.MERS-S) and the S1 extracellular domain of S protein (Ad5.MERS-S1). BALB/c mice were immunized with both candidate vaccines intramuscularly and boosted three weeks later intranasally. All the vaccinated animals had antibody responses against spike protein, which neutralized MERS-CoV in vitro. These results show that an adenoviral-based vaccine can induce MERS-CoV-specific immune responses in mice and hold promise for the development of a preventive vaccine that targets the animal reservoir, which might be an effective measure to eliminate transmission of MERS-CoV to humans.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0264-410X</s0>
</fA01>
<fA02 i1="01"><s0>VACCDE</s0>
</fA02>
<fA03 i2="1"><s0>Vaccine</s0>
</fA03>
<fA05><s2>32</s2>
</fA05>
<fA06><s2>45</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>EUN KIM</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>OKADA (Kaori)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KENNISTON (Tom)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>STALIN RAJ (V.)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>ALHAJRI (Mohd M.)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>FARAG (Elmoubasher A. B. A)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>ALHAJRI (Farhoud)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>OSTERHAUS (Albert D. M. E.)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>HAAGMANS (Bart L.)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>GAMBOTTO (Andrea)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Surgery, University of Pittsburgh School of Medicine</s1>
<s2>Pittsburgh, PA 15224</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Viroscience, Erasmus Medical Center Rotterdam</s1>
<s2>Rotterdam</s2>
<s3>NLD</s3>
<sZ>4 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Supreme Council of Health</s1>
<s2>Doha</s2>
<s3>QAT</s3>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Animal Resources Department - Ministry of Environment</s1>
<s2>Doha</s2>
<s3>QAT</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA20><s1>5975-5982</s1>
</fA20>
<fA21><s1>2014</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20289</s2>
<s5>354000508274440140</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2014 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>56 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>14-0250779</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Vaccine</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>A new type of coronavirus has been identified as the causative agent underlying Middle East Respiratory Syndrome (MERS). The MERS coronavirus (MERS-CoV) has spread in the Middle East, but cases originating in the Middle East have also occurred in the European Union and the USA. Eight hundred and thirty-seven cases of MERS-CoV infection have been confirmed to date, including 291 deaths. MERS-CoV has infected dromedary camel populations in the Middle East at high rates, representing an immediate source of human infection. The MERS-CoV spike (S) protein, a characteristic structural component of the viral envelope, is considered as a key target of vaccines against coronavirus infection. In an initial attempt to develop a MERS-CoV vaccine to ultimately target dromedary camels, we constructed two recombinant adenoviral vectors encoding the full-length MERS-CoV S protein (Ad5.MERS-S) and the S1 extracellular domain of S protein (Ad5.MERS-S1). BALB/c mice were immunized with both candidate vaccines intramuscularly and boosted three weeks later intranasally. All the vaccinated animals had antibody responses against spike protein, which neutralized MERS-CoV in vitro. These results show that an adenoviral-based vaccine can induce MERS-CoV-specific immune responses in mice and hold promise for the development of a preventive vaccine that targets the animal reservoir, which might be an effective measure to eliminate transmission of MERS-CoV to humans.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A05F04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002A05C10</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Coronavirus</s0>
<s2>NW</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Souris</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Mouse</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Ratón</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Immunogénicité</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Immunogenicity</s0>
<s5>05</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Inmunogenicidad</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Moyen Orient</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Middle east</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Oriente Medio</s0>
<s2>NG</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Vaccin</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Vaccine</s0>
<s5>07</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Vacuna</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Codon</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Codon</s0>
<s5>08</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Codón</s0>
<s5>08</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Coronaviridae</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Nidovirales</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Virus</s0>
<s2>NW</s2>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Asie</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Asia</s0>
<s2>NG</s2>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Asia</s0>
<s2>NG</s2>
</fC07>
<fN21><s1>307</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
<server><NO>PASCAL 14-0250779 INIST</NO>
<ET>Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice</ET>
<AU>EUN KIM; OKADA (Kaori); KENNISTON (Tom); STALIN RAJ (V.); ALHAJRI (Mohd M.); FARAG (Elmoubasher A. B. A); ALHAJRI (Farhoud); OSTERHAUS (Albert D. M. E.); HAAGMANS (Bart L.); GAMBOTTO (Andrea)</AU>
<AF>Department of Surgery, University of Pittsburgh School of Medicine/Pittsburgh, PA 15224/Etats-Unis (1 aut., 2 aut., 3 aut., 10 aut.); Department of Viroscience, Erasmus Medical Center Rotterdam/Rotterdam/Pays-Bas (4 aut., 8 aut., 9 aut.); Supreme Council of Health/Doha/Qatar (5 aut., 6 aut.); Animal Resources Department - Ministry of Environment/Doha/Qatar (7 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Vaccine; ISSN 0264-410X; Coden VACCDE; Royaume-Uni; Da. 2014; Vol. 32; No. 45; Pp. 5975-5982; Bibl. 56 ref.</SO>
<LA>Anglais</LA>
<EA>A new type of coronavirus has been identified as the causative agent underlying Middle East Respiratory Syndrome (MERS). The MERS coronavirus (MERS-CoV) has spread in the Middle East, but cases originating in the Middle East have also occurred in the European Union and the USA. Eight hundred and thirty-seven cases of MERS-CoV infection have been confirmed to date, including 291 deaths. MERS-CoV has infected dromedary camel populations in the Middle East at high rates, representing an immediate source of human infection. The MERS-CoV spike (S) protein, a characteristic structural component of the viral envelope, is considered as a key target of vaccines against coronavirus infection. In an initial attempt to develop a MERS-CoV vaccine to ultimately target dromedary camels, we constructed two recombinant adenoviral vectors encoding the full-length MERS-CoV S protein (Ad5.MERS-S) and the S1 extracellular domain of S protein (Ad5.MERS-S1). BALB/c mice were immunized with both candidate vaccines intramuscularly and boosted three weeks later intranasally. All the vaccinated animals had antibody responses against spike protein, which neutralized MERS-CoV in vitro. These results show that an adenoviral-based vaccine can induce MERS-CoV-specific immune responses in mice and hold promise for the development of a preventive vaccine that targets the animal reservoir, which might be an effective measure to eliminate transmission of MERS-CoV to humans.</EA>
<CC>002A05F04; 002A05C10</CC>
<FD>Coronavirus; Souris; Immunogénicité; Moyen Orient; Vaccin; Codon</FD>
<FG>Coronaviridae; Nidovirales; Virus; Rodentia; Mammalia; Vertebrata; Asie</FG>
<ED>Coronavirus; Mouse; Immunogenicity; Middle east; Vaccine; Codon</ED>
<EG>Coronaviridae; Nidovirales; Virus; Rodentia; Mammalia; Vertebrata; Asia</EG>
<SD>Coronavirus; Ratón; Inmunogenicidad; Oriente Medio; Vacuna; Codón</SD>
<LO>INIST-20289.354000508274440140</LO>
<ID>14-0250779</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000006 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000006 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    MersV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:14-0250779
   |texte=   Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice
}}

This area was generated with Dilib version V0.6.33.
Data generation: Mon Apr 20 23:26:43 2020. Site generation: Sat Mar 27 09:06:09 2021

	Serveur d'exploration MERS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration MERS

Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice

Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri